About Calimmune
Calimmune is a company based in Tucson (United States) founded in 2006 was acquired by CSL Behring in August 2017. Calimmune has raised $15.85 million across 1 funding round from investors including ARE, RA Capital and CSL Behring. The company has 23 employees. Calimmune operates in a competitive market with competitors including Insitro, BridgeBio, Adaptive Biotechnologies, Moderna and ATAI, among others.
- Headquarter Tucson, United States
- Employees 23
- SectorsHealthcare
- Website calimmune.com
- Social LinkedIn
- Acquired by CSL Behring (Aug 2017)
- Total Equity Funding$15.85M (USD)
in 1 rounds
- Latest Funding Round$15.85M (USD), Series B
May 2015
- InvestorsARE
& 2 more
- Employee Count23
- Acquired byCSL Behring
(Aug 2017)
Funding Insights of Calimmune
Calimmune has successfully raised a total of $15.85M through 1 strategic funding round. The most recent funding activity was a Series B round of $15.85 million completed in May 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $15.85M
- Total Rounds 1
- Last Round Series B — $15.85M
- First Round $15.85M
(May 2015)
- Investors Count 2
All 1 funding rounds of Calimmune with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2015 | $15.85M | Series B | – | – |
3 investors in total: 3 institutional.
Investors in Calimmune
Calimmune has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include ARE, RA Capital and CSL Behring.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
REIT that invests in campuses, multi-tenant spaces and build-to-suit facilities in the US | 1994 | are.com | Pasadena, United States | |
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
Developer of therapeutic solutions for the treatment of coagulation disorder | 2009 | cslbehring.com | King Of Prussia, United States |
Investor details for Calimmune
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Calimmune
3 dated milestones of Calimmune across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Calimmune is founded.
- Funding First funding round of $15.9M.
- Exit Acquired by CSL Behring.
Competitors of Calimmune
Calimmune operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, Adaptive Biotechnologies, Moderna and ATAI, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | – | Therapeutics for genetic diseases are developed through targeted interventions. | |
| adaptivebiotech.com | 2009 | Seattle, United States | $419.15M | 609 | Clinical diagnostics and drug discovery for immune diseases are provided. | |
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| atai.life | 2018 | Munich, Germany | $386.67M | – | A biopharmaceutical company accelerating innovative mental health treatments. | |
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| cariboubio.com | 2011 | Berkeley, United States | $156.55M | 92 | Provider of cell therapies to treat cancer and hematologic conditions | |
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes |
Detailed competitors of Calimmune
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Calimmune
Complete news archive for Calimmune
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Calimmune
10 companies that operate in the same segment as Calimmune (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Calimmune
Calimmune was founded in 2006 and raised its 1st funding round 9 years after it was founded.
Calimmune is headquartered in Tucson, United States. It is registered at Tucson, Arizona, United States.
Calimmune is a funded company, having raised a total of $15.85M across 1 funding round to date. The company's 1st funding round was a Series B of $15.85M, raised on May 2015.
Calimmune has 23 employees.
Developer of autologous cell therapies to enhance immune response for infectious diseases. The companys focus is on the development of AIDS therapies by targeting the CC5 proteins that are used by HIV to infect T-cells. It has been developed by the patients own stem cells to reduce the production of CC5 proteins, in addition to modifying mature T-cells to block HIV entry.
Calimmune's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Calimmune has 3 investors. Key investors include ARE, RA Capital, and CSL Behring.
Yes. Calimmune was acquired by CSL Behring in August 2017.